Satsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference
Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) announced that President and CEO John Kollins will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 3:00 p.m. (ET). The presentation will be in a virtual fireside chat format, with an option for investors to participate via webcast. Satsuma is developing STS101, a novel dihydroergotamine nasal powder for acute migraine treatment, aiming to improve patient experience compared to existing DHE products.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference and invites investors to participate via webcast. Please see additional details below:
11th Annual SVB Leerink Global Healthcare Conference (virtual)
| Date: | Thursday, February 17th |
| Time: | 3:00 p.m. (ET) |
| Speaker: | John Kollins, President & CEO of Satsuma Pharmaceuticals, Inc. |
| Format: | Fireside Chat |
| Webcast: | Registration Link – Click Here |
* a replay will be available following the presentation for 90 days
Please contact your representative at SVB Leerink to schedule a virtual one-on-one meeting with Satsuma Pharmaceuticals during the respective conference.
For information about the 11th Annual SVB Leerink Global Healthcare Conference, please refer to the events website.
About Satsuma Pharmaceuticals and STS101
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of migraine. STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device. STS101 is designed to provide significant benefits versus existing acute treatments for migraine, including the combination of quick and convenient self-administration and other clinical advantages, that current DHE liquid nasal spray products and injectable dosage forms lack. Satsuma’s dry powder DHE formulation has demonstrated fast absorption, rapid achievement of high DHE plasma concentrations which Satsuma believes is necessary for early efficacy, and sustained plasma levels over time with low dose to dose variability. STS101 also now incorporates an improved 2nd-generation nasal delivery device designed to provide more consistent nasal dosing, irrespective of user administration technique. Although DHE has long been recommended in published migraine treatment guidelines as a first-line acute treatment option for migraine and has significant advantages versus other anti-migraine treatments for many patients, disadvantages of current DHE liquid nasal spray and injectable products, including invasive and burdensome administration processes and/or sub-optimal clinical performance, have limited the widespread use of DHE. Featuring a compact and convenient dosage form, STS101 is designed to overcome these shortcomings and provide patients an improved therapeutic solution for acutely treating migraines that consistently delivers robust clinical performance.
Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.
INVESTOR AND CORPORATE CONTACTS:
Corey Davis, PhD
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
tom@satsumarx.com
FAQ
What is the date and time of Satsuma Pharmaceuticals' presentation at the SVB Leerink Global Healthcare Conference?
Who is the speaker for Satsuma Pharmaceuticals at the conference?
How can investors participate in Satsuma Pharmaceuticals' conference presentation?
What is STS101 developed by Satsuma Pharmaceuticals?
What advantages does STS101 offer compared to existing migraine treatments?
